ATE482207T1 - Cyclische harnstoffderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung als kinaseinhibitoren - Google Patents

Cyclische harnstoffderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung als kinaseinhibitoren

Info

Publication number
ATE482207T1
ATE482207T1 AT04705838T AT04705838T ATE482207T1 AT E482207 T1 ATE482207 T1 AT E482207T1 AT 04705838 T AT04705838 T AT 04705838T AT 04705838 T AT04705838 T AT 04705838T AT E482207 T1 ATE482207 T1 AT E482207T1
Authority
AT
Austria
Prior art keywords
production
kinase inhibitors
pharmaceutical use
urea derivatives
cyclic urea
Prior art date
Application number
AT04705838T
Other languages
English (en)
Inventor
Marcel Patek
Anil Nair
Augustin Hittinger
Conception Nemecek
Daniel Bond
Greg Harlow
Herve Bouchard
Jacques Mauger
Jean-Luc Malleron
Mark Palermo
Fahad Al-Obeidi
Thomas Faitg
Hartmut Strobel
Sven Ruf
Kurt Ritter
Youssef El-Ahmad
Dominique Lesuisse
Didier Benard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE482207T1 publication Critical patent/ATE482207T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT04705838T 2003-01-31 2004-01-28 Cyclische harnstoffderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung als kinaseinhibitoren ATE482207T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301098A FR2850652B1 (fr) 2003-01-31 2003-01-31 Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
PCT/FR2004/000188 WO2004070050A2 (fr) 2003-01-31 2004-01-28 Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
ATE482207T1 true ATE482207T1 (de) 2010-10-15

Family

ID=32696243

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04705838T ATE482207T1 (de) 2003-01-31 2004-01-28 Cyclische harnstoffderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung als kinaseinhibitoren

Country Status (24)

Country Link
EP (1) EP1599464B1 (de)
JP (1) JP4604020B2 (de)
KR (1) KR20050098286A (de)
CN (1) CN1768054A (de)
AR (1) AR042936A1 (de)
AT (1) ATE482207T1 (de)
AU (1) AU2004209319A1 (de)
BR (1) BRPI0407091A (de)
CA (1) CA2513631A1 (de)
DE (1) DE602004029236D1 (de)
FR (1) FR2850652B1 (de)
HR (1) HRP20050679A2 (de)
MA (1) MA27651A1 (de)
ME (1) MEP22608A (de)
MX (1) MXPA05007407A (de)
NO (1) NO20054006L (de)
NZ (1) NZ541270A (de)
PE (1) PE20040808A1 (de)
PL (1) PL377811A1 (de)
RS (1) RS20050657A (de)
RU (1) RU2341523C2 (de)
TW (1) TW200505898A (de)
WO (1) WO2004070050A2 (de)
ZA (1) ZA200505934B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491743B2 (en) * 2003-08-29 2009-02-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP1621535A1 (de) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Cyclische Substituirte Harnstoffderivate, Verfahren zu ihrer Herstellung, und ihre pharmazeutische Verwendung als Kinase Inhibitoren
EP1621536A1 (de) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino zyklische Urea-Derivaten, ihre Herstellung und deren pharmazeutische Verwendungen als Kinase Inhibitoren
EP3106162A1 (de) 2005-05-13 2016-12-21 The Regents of the University of California Diarylhydantoinverbindungen als androgene rezeptorantagonisten zur behandlung von krebs
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP2656842B1 (de) * 2006-03-27 2016-08-10 The Regents of The University of California Androgenrezeptor-modulator zur behandlung von prostatakrebs und androgenrezeptor-assoziierte erkrankungen
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
CA2772760A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
HUE037389T2 (hu) 2010-02-16 2018-08-28 Aragon Pharmaceuticals Inc Androgén receptor modulátorok és alkalmazásaik
BR112013014871B1 (pt) * 2010-12-21 2020-04-28 Cytec Tech Corp método para produção de uma microdispersão
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
CA3105575A1 (en) 2013-01-15 2014-07-24 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
GB201312492D0 (en) * 2013-07-12 2013-08-28 Syngenta Ltd Herbicidal compounds
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
EP3094326A4 (de) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryle und verwendungen davon
EP3229807A4 (de) 2014-12-11 2018-10-17 President and Fellows of Harvard College Hemmer von zellulärer nekrose und zugehörige verfahren
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
US10710980B2 (en) * 2016-07-20 2020-07-14 Novartis Ag Aminopyridine derivatives and their use as selective ALK-2 inhibitors
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
KR102247795B1 (ko) * 2017-10-31 2021-05-04 주식회사 펠레메드 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
TW202517640A (zh) * 2023-07-18 2025-05-01 愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司 用於治療疾病之ｉｇｆ－１ｒ的雜環抑制劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
EP0966447B1 (de) * 1997-03-03 2003-03-05 Boehringer Ingelheim Pharmaceuticals Inc. Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
ES2284641T3 (es) * 2000-05-31 2007-11-16 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion celular mediada por alfa-l-beta-2.
BR0309972A (pt) * 2002-05-16 2005-03-01 Bayer Cropscience Gmbh Derivados de piridina carboxamida e seu uso como pesticidas

Also Published As

Publication number Publication date
CA2513631A1 (fr) 2004-08-19
RU2341523C2 (ru) 2008-12-20
CN1768054A (zh) 2006-05-03
JP4604020B2 (ja) 2010-12-22
WO2004070050A3 (fr) 2005-02-17
NZ541270A (en) 2008-11-28
FR2850652B1 (fr) 2008-05-30
BRPI0407091A (pt) 2006-01-24
MA27651A1 (fr) 2005-12-01
AR042936A1 (es) 2005-07-06
JP2006517569A (ja) 2006-07-27
MEP22608A (en) 2010-06-10
MXPA05007407A (es) 2005-09-12
NO20054006L (no) 2005-10-13
EP1599464B1 (de) 2010-09-22
TW200505898A (en) 2005-02-16
RS20050657A (sr) 2007-06-04
PE20040808A1 (es) 2004-12-31
RU2005127335A (ru) 2006-09-10
EP1599464A2 (de) 2005-11-30
DE602004029236D1 (de) 2010-11-04
FR2850652A1 (fr) 2004-08-06
AU2004209319A1 (en) 2004-08-19
ZA200505934B (en) 2007-06-27
NO20054006D0 (no) 2005-08-29
HRP20050679A2 (en) 2006-12-31
KR20050098286A (ko) 2005-10-11
PL377811A1 (pl) 2006-02-20
WO2004070050A2 (fr) 2004-08-19

Similar Documents

Publication Publication Date Title
ATE482207T1 (de) Cyclische harnstoffderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung als kinaseinhibitoren
ATE470666T1 (de) Arylsubstituierte heterozyklen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE438645T1 (de) 7-phenylamino-4-chinolon-3-carbonsäure-derivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE452879T1 (de) Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE502005010912D1 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE50312949D1 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
ATE265424T1 (de) Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE502005007786D1 (de) Ausgewahlte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE502004007000D1 (de) Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE502004011957D1 (de) Neue cyanopyrrolidide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE381564T1 (de) Arylsubstituierte polycyclische amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1840122A4 (de) Aminopyrimidinverbindungen und ihre salze, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE502004011328D1 (de) Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE50309807D1 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE10393704D2 (de) Nancomposite, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE348609T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
ATE498618T1 (de) Neue zyklische harnstoffderivate, deren herstellung und pharmazeutische verwendung damit als kinase-inhibitoren
DE502004002117D1 (de) Substituierte thiazol-benzoisothiazoldioxidderivative, verfahren zu deren herstellung und deren verwendung
DE602004029245D1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
ATE327981T1 (de) Arylisoxazolin-derivative, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
ATE323092T1 (de) Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE478066T1 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
ATE473738T1 (de) 1-sulfonylindolderivate, verfahren zu ihrer herstellung und ihre verwendung als 5-ht6 liganden
DE602004010229D1 (de) Polyenpolyketide, verfahren zu deren herstellung und deren verwendung als pharmazeutikum
DE602006019731D1 (de) 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties